SCHEMBL23328880

SCHEMBL23328880

CC(C)c1ccc(-c2cnn(C)n2)cc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AOC3 Q16853 2/20 0.42
LMNA P02545 2/20 0.38
DGAT1 O75907 1/20 0.38
TP53 P04637 2/20 0.37
USP2 O75604 1/20 0.37
CYP1A2 P05177 1/20 0.37
CYP2C9 P11712 1/20 0.37
ALOX15 P16050 1/20 0.37
CASP3 P42574 1/20 0.37
SENP8 Q96LD8 1/20 0.37
SENP7 Q9BQF6 1/20 0.37
SENP6 Q9GZR1 1/20 0.37
CHRM2 P08172 1/20 0.37
CHRM3 P20309 1/20 0.37
TMEM97 Q5BJF2 1/20 0.36
SIGMAR1 Q99720 1/20 0.36
EP300 Q09472 6/20 0.36
RAB9A P51151 2/20 0.36
NPC1 O15118 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5048013 0.81 AOC3 (0.43) AOC3LMNATP53USP2CHRM2
SCHEMBL11730368 0.81 KEAP1 (0.55) AOC3LMNATP53ALOX15CHRM2
SCHEMBL19245814 0.79 CHRM2 (0.35) AOC3LMNADGAT1CHRM2CHRM3
SCHEMBL5053616 0.77 AOC3 (0.47) AOC3LMNATP53CHRM2CHRM3
Ammonia Solution, Strong SCHEMBL28862485 0.77 AOC3 (0.43) AOC3LMNATP53CYP1A2CYP2C9
SCHEMBL5047902 0.77 AOC3 (0.47) AOC3LMNACHRM2CHRM3RAB9A
SCHEMBL21412297 0.77 AOC3 (0.47) AOC3TP53USP2CHRM2CHRM3
SCHEMBL5049537 0.76 AHR (0.45) AOC3LMNACYP1A2CYP2C9RAB9A
SCHEMBL5047974 0.74 AOC3 (0.51) AOC3LMNACASP3SENP7RAB9A
SCHEMBL9258776 0.73 KEAP1 (0.66) LMNATP53USP2CYP1A2CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11806335-B2 Heterocyclic carboxylate compounds as glycolate oxidase inhibitors Lilac Therapeutics, Inc. (US) 2023-11-07 US disclosed
US-11806335-B2 Heterocyclic carboxylate compounds as glycolate oxidase inhibitors Lilac Therapeutics, Inc. (US) 2023-11-07 US disclosed
US-20210128532-A1 HETEROCYCLIC CARBOXYLATE COMPOUNDS AS GLYCOLATE OXIDASE INHIBITORS Lilac Therapeutics, Inc. 2021-05-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11806335-B2 Heterocyclic carboxylate compounds as glycolate oxidase inhibitors UGDH, PGD, PNPO AOC3 24/4885LMNA 4767/4885DGAT1 313/4885
US-20210128532-A1 HETEROCYCLIC CARBOXYLATE COMPOUNDS AS GLYCOLATE OXIDASE INHIBITORS UGDH, PGD, PNPO AOC3 24/4885LMNA 4767/4885DGAT1 313/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.